Medac Will Market Fresenius Kabi’s Adalimumab In Germany
Collaboration On Idacio Will Begin From The Start Of June
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
